Arena Pharmaceuticals Inc.
www.arenapharm.com
Latest From Arena Pharmaceuticals Inc.
Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial
Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.
Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?
Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.
Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cardiovascular
- Gastrointestinal
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Arena Pharmaceuticals Inc.
- Senior Management
-
Amit Munshi, Pres. & CEO
Kevin R Lind, EVP, CFO
Vince Aurentz, EVP, CBO
Preston Klassen, MD, EVP, R&D & CMO - Contact Info
-
Arena Pharmaceuticals Inc.
Phone: (858) 453-7200
6154 Nancy Ridge Dr.
San Diego, CA 92121
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice